SREBF1 and pancreatic neoplasm: Moreover, it has been found to inhibit lipid synthesis via SREBP1 inhibition in MiaPaCa-2 and Panc-1 pancreatic cancer cells in the dose of 50 μmol/L as well as in a transgenic mouse model of pancreatic cancer in the dose of 50 mg/kg body weight [100] or to reduce breast tumor volume concomitantly with the reduction of lipid content in serum in female nude mice in the dose of 22.4 mg/kg body weight [101].